ALLO
Allogene Therapeutics Inc - Cema-Cel Achieves Orr of 58% and Cr of 42% in Study
时间：2025-02-14 05:30:30 市场： 美股 综合
Allogene Therapeutics Announces Publication of Durable Response Data From Phase 1 Alpha/Alpha2 Trials of the Allogeneic Car T Cemacabtagene Ansegedleucel/Allo-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology
时间：2025-02-14 05:30:30 市场： 美股 综合
Allogene Therapeutics Secures U.S. FDA Ind Clearance for Allo-329, Advancing Its Next-Generation Allogeneic Car T Into Autoimmune Diseases
时间：2025-01-28 21:30:02 市场： 美股 综合
Allogene Therapeutics Inc : Qtrly Shr Loss $0.32
时间：2024-11-08 06:06:55 市场： 综合 美股
Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of Allo-316 in Heavily Pretreated Patients With Advanced Renal Cell Carcinoma at SITC and Ikcs
时间：2024-11-07 23:00:01 市场： 美股 综合
Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update
时间：2024-10-30 20:30:01 市场： 综合 美股
Artiva Biotherapeutics Appoints Alison Moore, Ph.d., to Its Board of Directors
时间：2024-10-23 04:05:02 市场： 综合 美股